Get the Stockscreener App
24.67
5.34%
1.25
After Hours:
25.74
1.07
+4.34%
Gh Research Plc stock is traded at $24.67, with a volume of 1.13M.
It is up +5.34% in the last 24 hours and down -11.70% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$23.42
Open:
$23.39
24h Volume:
1.13M
Relative Volume:
4.38
Market Cap:
$1.69B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-31.23
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
-11.45%
1M Performance:
-11.70%
6M Performance:
+87.60%
1Y Performance:
+69.79%
1-Day Range:
$23.12
$24.99
1-Week Range:
$22.89
$28.13
52-Week Range:
$12.04
$31.44
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
24.67 | 1.64B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
526.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
203.46 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
750.51 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
970.66 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.48 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research PLC (1KA.HM) Stock Forum & Discussion - Yahoo! Finance Canada
GH Research PLC (1KA.HM) - Yahoo! Finance Canada
GH Research PLC (1KA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
GH Research PLC (1KA.HM) balance sheet – Yahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) insider ownership and holdings – Yahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) valuation measures and financial statistics - Yahoo Finance Singapore
GH Research PLC (1KA.HM) company profile and factsYahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) income statement – Yahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) analyst ratings, estimates and forecasts – Yahoo Finance - Yahoo Finance Singapore
GH Research PLC (1KA.HM) stock historical prices and data - Yahoo Finance Singapore
GH Research PLC (1KA.HM) stock price, news, quote and history - Yahoo Finance Singapore
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research gets FDA clearance to start phase 3 trial for new depression treatment in 2026 - Pluang
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities - Seeking Alpha
GH Research PLC (GHRS): Investor Outlook on a Biotech Stock with a 49% Potential Upside - DirectorsTalk Interviews
GH Research PLC (NASDAQ: GHRS) Files September 2026 Report Under 1934 Exchange Act - kalkinemedia.com
GH Research PLC (GHRS) Stock Price Quote Today & Current Price Chart - Capital.com
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference - TipRanks
$GHRS Q2 '26 Earnings Results & Recap - Stocktwits
GH Research (GHRS) plans one-on-one talks at 2026 Morgan Stanley healthcare event - Stock Titan
Price-Driven Insight from (GHRS) for Rule-Based Strategy - news.stocktradersdaily.com
GH Research (GHRS) director gets 2,303 options not exercisable until 2028 - Stock Titan
GH Research PLC (GHRS) Dips 1.56% as Shares Sit at Midpoint of Trading RangeEarnings Quality Factor - dars.gov.et
GHRS Q2 2026 Earnings: Loss Narrows More Than Expected as Investors Focus on PipelineEarnings Stability Report - dars.gov.et
(GHRS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
GH Research (GHRS) Slides 2.48% to $27.94 as Shares Approach Key SupportBearish Pattern Stocks - vinanet.vn
Net margin % of GH Research Plc – HAM:1KA - TradingView
Net income before discontinued operations of GH Research Plc – HAM:1KA - TradingView
GH Research Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
How Rising Losses And Milestone Spending At GH Research (GHRS) Have Changed Its Investment Story - simplywall.st
GHRS Q2 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 25.6%Earnings Trend Analysis - vinanet.vn
Zacks Research Upgrades GH Research (NASDAQ:GHRS) to Hold - MarketBeat
GHRS Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Takes Center Stage - dars.gov.et
RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan
Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC Director Duncan Moore Granted 2,202 Share Options - Kalkine Media
GH Research PLC (GHRS) director receives 2,202 fully vested share options - Stock Titan
GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike - Stock Titan
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
GHRS Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 25.6% EPS SurpriseFull Year Guidance - dars.gov.et
GH Research (NASDAQ:GHRS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
FY2026 EPS Estimates for GH Research Boosted by Analyst - MarketBeat
GH Research (GHRS) Retreats 2.4% to $29.53 as Clinical-Stage Biotech ConsolidatesTechnical Analysis - siam.in
Trading the Move, Not the Narrative: (GHRS) Edition - Stock Traders Daily
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative? - simplywall.st
GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen - MarketBeat
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):